Biography for John Carroll
John D. Carroll,
Editor-in-Chief
John D. Carroll is a biotech analyst with 34 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered genomics, biotechnology, healthcare and other business topics for Managed Care, American Banker, Small Times, and Local Business.com, He has also contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and other leading publications. He spent six years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. He enjoys hiking, traveling and spending time with his family. Carroll is based in Vermont and Texas and can be reached at [email protected]. Follow @JohnCFierce on Twitter.
Articles by John Carroll
Dendreon's (
NASDAQ: DNDN) megablockbuster launch of the prostate cancer vaccine Provenge got an added boost earlier in the week when researchers unveiled a new block of data that underscores the
An experimental breast cancer vaccine being advanced by researchers at the Cleveland Clinic has been in the media spotlight for much of the week. Inside the center ring is immunologist Vincent Tuohy,
The nonprofit Immune Tolerance Institute is partnering with the David H. Murdock Research Institute to create an immune system research center at the biotech campus in Kannapolis, NC. "The potential
Beheading the hemagglutinin protein exposes a stable section of the molecule, and that may just prove the solution needed to develop a universal flu vaccine, according to a team of researchers at Mt.
Earlier this week a panel of medical experts in the UK banned Andrew Wakefield from practicing medicine in his native country after slamming him for professional misconduct while gathering
An experimental brain cancer vaccine developed at Duke University is being tested on patients at Duke and St. Vincent's Medical Center in Jacksonville, FL. The vaccine is made by extracting white
When the next pandemic hits, you can expect a huge number of people in the U.S. to steer clear of any new vaccine developed to prevent an outbreak. Many will not be quite sure of its safety, and
A group of researchers at Nottingham University in the UK are planning to launch a human trial of a new vaccine for metastatic melanoma. Professor Lindy Durrant, the head of research at the company...
One popular new game in biotech investment circles is guessing the cancer vaccine developer that is most likely to follow in the footsteps of Dendreon (
NASDAQ: DNDN), which braved some considerable
GlaxoSmithKline made a splash in the media several months ago when it
joined with Pfizer and announced that it would supply 30 million doses of vaccine each year to protect children in developing
